Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial.
| Autor: | Coles, A. J., Fox, E., Vladic, A., Gazda, S. K., Brinar, V., Selmaj, K. W., Skoromets, A., Stolyarov, I., Bass, A., Sullivan, H., Margolin, D. H., Lake, S. L., Moran, S., Palmer, J., Smith, M. S., Compston, D. A. S. |
|---|---|
| Zdroj: | Neurology; 4/3/2012, Vol. 78 Issue 14, p1069-1078, 10p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|